A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)

Summary

The goal of this study is to determine if Hylenex recombinant leads to changes in the insulin time-action profiles and glucose responses when preadministered in the setting of continuous subcutaneous insulin infusion (CSII) compared to CSII without Hylenex recombinant (sham injection).

Timeline

Start

2013-10-03

Primary completion

2014-02-27

Completion

2014-02-27

Outcome

Met primary endpoint

release “the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial” halozyme.com ↗

Drugs

Indications